Nuevocor, a Singapore-headquartered preclinical-stage biotech startup, has announced raising $24 million in an oversubscribed Series A funding round co-anchored by EVX Ventures and Boehringer Ingelheim Venture Fund (BIVF).
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
